Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
11 avr. 2022 17h54 HE
|
Revive Therapeutics Ltd.
TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
29 mars 2022 08h45 HE
|
Revive Therapeutics Ltd.
Expected to seek DSMB approval to proceed with EUA application to the FDA in Q2-2022 Ongoing regulatory package activities for submission to international regulatory authorities for drug approvals ...
Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation
15 févr. 2022 16h26 HE
|
Revive Therapeutics Ltd.
TORONTO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
14 févr. 2022 06h00 HE
|
Revive Therapeutics Ltd.
Ethics Committee approval to proceed with Phase 3 clinical trial in Turkey13 clinical sites selected to date in Turkey TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive”...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
18 janv. 2022 21h02 HE
|
Revive Therapeutics Ltd.
701 subjects dosed to dateInitiating enrollment activities in Turkey as part of its clinical diversification plans to support global regulatory approvals On-track to complete enrollment in Q1-2022 and...
Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs
17 janv. 2022 08h17 HE
|
Revive Therapeutics Ltd.
IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs TORONTO, Jan. 17, 2022 ...
Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19
06 janv. 2022 16h24 HE
|
Revive Therapeutics Ltd.
Approximately 700 subjects participated in the enrollment periodExpected to begin subject enrollment in Turkey by mid-FebruaryExpected to complete enrollment in Q1-2022 TORONTO, Jan. 06, 2022 ...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
29 déc. 2021 16h45 HE
|
Revive Therapeutics Ltd.
Screened approximately 700 subjects and expanding to Eastern Europe, including Turkey, as part of its clinical diversification plans to support global regulatory approvalsNo serious adverse events and...
UPDATE -- Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial
03 déc. 2021 09h31 HE
|
Revive Therapeutics Ltd.
Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529)Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2)Adding...
Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial
03 déc. 2021 08h30 HE
|
Revive Therapeutics Ltd.
Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529)Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2)Adding...